OSLN
This asset is not currently listed on any markets available through Pearler. The information on this page may be inaccurate or out of date.
Oncosil Medical Ltd
🇦🇺 ASX
🔭 LIFE SCIENCES TOOLS & SERVICES
👑 Overview
📈 Performance
💵 Cost
🤓 Advanced
👨👩👧👦 Community
📈
N/A
Annual Growth
5 years average annual growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
2
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
OncoSil Medical Ltd. develops and commercializes neurology services, including those for pancreatic cancer. The company is headquartered in North Sydney, New South Wales. The company went IPO on 2005-08-15. The firm is focused on the development and commercialization of its lead product candidate, OncoSil localized radiation therapy, for the treatment of pancreatic and distal cholangiocarcinoma. OncoSil is a targeted radioactive isotope (Phosphorus-32), implanted directly into a patient’s pancreatic tumors through an endoscopic ultrasound. OncoSil is a single-use brachytherapy device that has received breakthrough device designation in the European Union, the United Kingdom, and the United States for the treatment of unresectable locally advanced pancreatic cancer in combination with chemotherapy. OncoSil comprises phosphorous-32 microparticles suspended in a specially formulated diluent. OncoSil is indicated for the treatment of patients with locally advanced unresectable pancreatic cancer, in combination with gemcitabine-based chemotherapy.
📈 Performance
Price History
N/A
1M
All Time
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in OSLN
0
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
N/A
💵 Average investment amount
N/A
⏰ Last time a customer invested in OSLN
N/A
OSLN investor breakdown
💵 Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
👶 Age of investors
18 - 25
26 - 34
35 - 90
🙋 Legal gender of investors
Female
Male
Pearlers who invest in OSLN also invest in...
OncoSil Medical Ltd. develops and commercializes neurology services, including those for pancreatic cancer. The company is headquartered in Macquarie, New South Wales. The company went IPO on 2005-08-15. The firm is focused on the development and commercialization of its lead product candidate, the OncoSil localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. The firm has developed a cancer treatment device, the OncoSil brachytherapy device, which is a critical component of a brachytherapy treatment for locally advanced unresectable pancreatic cancer. The OncoSil device delivers a targeted intratumoral placement of Phosphorous-32 (32P) in the treatment of locally advanced unresectable pancreatic cancer. The OncoSil device has received a device designation in the European Union, United Kingdom and United States for the treatment of locally advanced unresectable pancreatic cancer in combination with chemotherapy.
🙌 Performance (5Yr p.a)
-19.06%
📊 Share price
$0.01 AUD
🔭 LIFE SCIENCES TOOLS & SERVICES
ASX
ASX Ltd. engages in operating a securities exchange. The company is headquartered in Sydney, New South Wales and currently employs 1,193 full-time employees. The firm is engaged in offering listings, trading, clearing, settlement, technical and information services, technology, data and other post-trade services. The company acts as a market operator, clearing house and payments system facilitator. The ASX operates markets for a range of asset classes including equities, fixed income, commodities, and energy. Its activities span primary and secondary market services, including the raising, allocation and hedging of capital flows; trading and price discovery; central counterparty risk transfer, and securities settlement for both the equities and fixed income markets. ASX operates through four divisions: listings, markets, technology and data, and securities and payments. The company also provides data and technology services to intermediaries, banks, information vendors and software developers to help them make decisions, offer services to their clients and connect with one another.
🙌 Performance (5Yr p.a)
-3.71%
📊 Share price
$66.03 AUD
🕊️ SOCIALLY AWARE
💸 FINANCIALS
Brickworks Ltd. engages in the manufacture and distribution of building products. The company is headquartered in Sydney, New South Wales and currently employs 1,850 full-time employees. Its segments include Building Products Australia, Building Products North America, Property and Investments. Building Products Australia and Building Products North America segments manufacture and supply vitrified clay and concrete products used in the building industry. Building Products Australia segment includes Austral Bricks (bricks producer) and other brands such as Austral Masonry and Bristile Roofing. Building Products North America segment includes the flagship brand of Glen-Gery. This segment's product lines include bricks, masonry blocks and accessories. Property segment utilizes opportunities associated with land owned by the Company, including the sale of property and investment in Property Trusts. Investments segment holds investments in the Australian share market, both for dividend income and capital growth, and includes the investment in Washington H. Soul Pattinson and Company Limited, and FBR Limited.
🙌 Performance (5Yr p.a)
7.07%
📊 Share price
$25.74 AUD
👷♀️ CONSTRUCTION
Energy Resources of Australia Ltd. engages in the sale of uranium oxide and site rehabilitation. The company is headquartered in Darwin, Northern Territory and currently employs 190 full-time employees. The principal activities of the Company consist of the site rehabilitation. The Company’s Ranger Mine area is located about eight kilometers (kms) east of Jabiru and approximately 260 kms east of Darwin, in Australia's Northern Territory. The company also holds title to the Jabiluka mineral lease. The Ranger Mine area and the Jabiluka mineral lease are located on Aboriginal land and are surrounded by, but separate from, the Kakadu National Park. The Ranger uranium mine lies approximately 79 square kilometers and is surrounded by, but separate from the Kakadu National Park, which is approximately 20,000 square kilometers. The Jabiluka estimated mineral resource is approximately 137,100 tons of uranium oxide.
🙌 Performance (5Yr p.a)
-18.77%
📊 Share price
$0.00 AUD
⚡️ ENERGY
A200.AX was created on 2018-05-07 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. A200.AX aims to track the performance of an index (before fees and expenses) comprising 200 of the largest companies by market capitalisation listed on the ASX.
🙌 Performance (5Yr p.a)
4.17%
📊 Share price
$137.87 AUD
💸 FINANCIALS
⛳️ DIVERSIFIED
🇦🇺 AUSTRALIA